TherapeuticsMD, Inc. (TXMD) News

TherapeuticsMD, Inc. (TXMD): $0.80

0.01 (+0.91%)

POWR Rating

Component Grades













Filter TXMD News Items

TXMD News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

TXMD News Highlights

  • For TXMD, its 30 day story count is now at 3.
  • Over the past 11 days, the trend for TXMD's stories per day has been choppy and unclear. It has oscillated between 1 and 1.

Latest TXMD News From Around the Web

Below are the latest news stories about TherapeuticsMD Inc that investors may wish to consider to help them evaluate TXMD as an investment opportunity.

TherapeuticsMD Announces Appointment of Mark Glickman as Chief Business Officer

BOCA RATON, Fla., October 15, 2021--TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading women’s healthcare company, today announced the appointment of Mark Glickman as the Company’s Chief Business Officer.

Yahoo | October 15, 2021

What Type Of Shareholders Own The Most Number of TherapeuticsMD, Inc. (NASDAQ:TXMD) Shares?

Every investor in TherapeuticsMD, Inc. ( NASDAQ:TXMD ) should be aware of the most powerful shareholder groups...

Yahoo | October 5, 2021

Where Do Hedge Funds Stand On TherapeuticsMD Inc (TXMD)?

After several tireless days we have finished crunching the numbers from nearly 900 13F filings issued by the elite hedge funds and other investment firms that we track at Insider Monkey, which disclosed those firms’ equity portfolios as of June 30th. The results of that effort will be put on display in this article, as […]

Yahoo | October 4, 2021

If You Invested $1,000 In TherapeuticsMD Stock One Year Ago, Here''s How Much You''d Have Now

Investors who have owned stocks in the last year have generally experienced some big gains. In fact, the SPDR S&P 500 ETF Trust (NYSE: SPY ) total return over the last 12 months is 33.6%. But there is no question some big-name stocks performed better than others along the way. TherapeuticsMDs Difficult Year: One company that has been a horrible investment in the last year has been pharmaceutical stock TherapeuticsMD Inc (NASDAQ: TXMD ). TherapeuticsMDs key technology is SYMBODA, a technology used to develop advanced hormone therapy pharmaceutical products for women. The company also produces prescription prenatal vitamins and over-the-counter vitamins under the BIJUVA, IMVEXXY, vitaMedMD and BocaGreenMD brands. Related Link: If You Invested $1,000 In BioNano Stock One Year Ago, Here''s ...

Benzinga | September 17, 2021

Therapeutics MD Is Urging Women to ‘Take Pause’ During Menopause Awareness Month

BOCA RATON, Fla., September 02, 2021--This September, TherapeuticsMD, Inc., an innovative women’s healthcare company (NASDAQ: TXMD), is recognizing Menopause Awareness Month, as it aims to empower the 64 million women in the U.S. currently in menopauseii. To celebrate this month and all menopausal women, TherapeuticsMD encourages people to Take Pause and learn about menopause.

Yahoo | September 2, 2021

TherapeuticsMD Announces Issuance of a J-Code for ANNOVERA® to Be Utilized in the Public Health Sector

BOCA RATON, Fla., August 23, 2021--TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading women’s healthcare company, today announced that the Centers for Medicare and Medicaid Services (CMS) confirmed its preliminary recommendation to assign a permanent product-specific Healthcare Common Procedure Coding System (HCPCS) J Code for ANNOVERA (segesterone acetate and ethinyl estradiol vaginal system). As a result, CMS established the new HCPCS Level II code J7294 "Segesterone acetate and ethin

Yahoo | August 23, 2021

5 Penny Stocks Insiders Are Buying

When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform. TherapeuticsMD The Trade: TherapeuticsMD, Inc. (NASDAQ: TXMD) Director Paul Bisaro acquired a total of 50000 shares at an

Yahoo | August 19, 2021

TherapeuticsMD Announces Appointment of Hugh O’Dowd as President

BOCA RATON, Fla., August 09, 2021--TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading women’s healthcare company, today announced the appointment of Hugh O’Dowd as President. Mr. O’Dowd succeeds John C.K. Milligan, IV, who the Company recently appointed as Chief Executive Officer of its vitaCare Prescription Services business.

Yahoo | August 9, 2021

TherapeuticsMD (TXMD) Reports Q2 Loss, Tops Revenue Estimates

TherapeuticsMD (TXMD) delivered earnings and revenue surprises of 0.00% and 1.64%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | August 4, 2021

TherapeuticsMD Announces Second Quarter 2021 Financial Results

BOCA RATON, Fla., August 04, 2021--TherapeuticsMD, Inc. ("TXMD" or the "Company") (NASDAQ: TXMD), an innovative, leading women’s healthcare company, today reported financial results for the second quarter ended June 30, 2021.

Yahoo | August 4, 2021

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.6497 seconds.